Clinical Evaluation of Dementia and When to Perform PET

  • Linda M. Ercoli
  • Gary W. Small

The number and proportion of adults over 65 years is expected to increase rapidly over the next several decades. According to projections from the United States Bureau of the Census, 1 between the years 2000 and 2030, the population aged 65 and over is expected to double from 35 to over 70 million. The largest proportion of older adults will be between the ages of 65 and 74 years, and the largest growth is projected to occur in individuals 85 years and older, increasing from 4.3 to 8.8 million. Because age is the greatest risk factor for dementia, as the population of elderly people increases, so will the number of patients suffering from dementia. Given that early treatment interventions are able to keep patients at higher levels of functioning and future innovative therapies may be able to delay the onset of dementia and slow its progression, it is becoming increasingly important to accurately diagnose dementia as early as possible. This chapter outlines the basic elements of a clinical diagnostic evaluation for Alzheimer’s disease (AD) and other dementias; and also addresses how to identify candidates for a dementia evaluation, discusses the role of neuroimaging in a clinical dementia evaluation, and identifies future directions


Positron Emission Tomography Single Photon Emission Compute Tomography Mild Cognitive Impairment Dementia With Lewy Body Clinical Dementia Evaluation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    US Bureau of the Census. Population projections of the United States by race, sex, age and Hispanic origin: 1995–2050. Current Pop Rep 2000;25–1130.Google Scholar
  2. 2.
    American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC: APA, 1994.Google Scholar
  3. 3.
    3. Rasmusson DX, Brandt J, Steele C,. Accuracy of clinical diagnosis of Alzheimer disease and clinical features of patients with non-Alzheimer neuropathology. Alzheimer Dis Assoc Disord 1996;10:180–188.PubMedGoogle Scholar
  4. 4.
    4. Larson EB, Edwards JK, O'Meara E,. Neuropathologic diagnostic outcomes from a cohort of outpatients with suspected dementia. J Gerontol 1996;51:M313–318.Google Scholar
  5. 5.
    5. McKhann G, Drachman D, Folstein M,. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984;34:939–944.PubMedGoogle Scholar
  6. 6.
    6. Ferri CP, Prince M, Brayne C,. Global prevalence of dementia: a Delphi consensus study. Lancet 2005;366:2112–2117.PubMedGoogle Scholar
  7. 7.
    7. Bachman DL, Wolf PA, Linn RT,. Incidence of dementia and probable Alzheimer's disease in a general population: the Framingham study. Neurology 1993;43:515–519.PubMedGoogle Scholar
  8. 8.
    8. Jorm AF. The epidemiology of Alzheimer's disease and related disorders. London: Chapman & Hall, 1990.Google Scholar
  9. 9.
    9. Ritchie K, Kildea D. Is senile dementia “age related” or “aging related?” Evidence from a meta-analysis of dementia prevalence in the oldest old. Lancet 1995;346:931–934.PubMedGoogle Scholar
  10. 10.
    National Institute on Aging. Progress report on Alzheimer’s disease 1996. Bethesda: National Institute on Aging; NIH Publication No 96-4137, 1996.Google Scholar
  11. 11.
    11. Ernst RL, Hay JW. The US economic and social costs of Alzheimer's disease revisited. Am J Public Health 1994;84:1261–1264.PubMedGoogle Scholar
  12. 12.
    12. Brayne C, Gill C, Huppert FA,. Incidence of clinically diagnosed subtypes of dementia in an elderly population. Cambridge Project for Later Life. Br J Psychiatr 1995;167:255–262.Google Scholar
  13. 13.
    13. Hebert R, Brayne C. Epidemiology of vascular dementia. Neuroepidemiology 1995;14:240–257.PubMedGoogle Scholar
  14. 14.
    14. Ikeda M, Hokoishi K, Maki N,. Increased prevalence of vascular dementia in Japan: a community-based epidemiological study. Neurology 2001;57:839–844.PubMedGoogle Scholar
  15. 15.
    15. Zaccai J, McCracken C, Brayne C. A systematic review of prevalence and incidence studies of dementia with Lewy bodies. Age Ageing 2005;34:561–566.PubMedGoogle Scholar
  16. 16.
    16. Galariotis V, Bodi N, Janka Z,. Frontotemporal dementia—part I. History, prevalence, clinical forms. Ideggyogy Sz 2005;20:164–171.Google Scholar
  17. 17.
    17. Snowden JS, Neary D, Mann DM. Frontotemporal dementia. Br J Psychiatr 2002;180:140–143.Google Scholar
  18. 18.
    18. DeKosky S. Early intervention is key to successful management of Alzheimer disease. Alzheimer Dis Assoc Disord 2003;17(Suppl 4):S99–104.PubMedGoogle Scholar
  19. 19.
    19. Leifer BP. Early diagnosis of Alzheimer's disease: clinical and economic benefits. J Am Geriatr Soc 2003;51(5 Suppl Dementia):S281–288.PubMedGoogle Scholar
  20. 20.
    20. Crook T, Bartus RT, Ferris SH,. Age associated memory impairment: proposed diagnostic criteria and measures of clinical change—report of a National Institute of Mental Health Work Group. Dev Neuropsychol 1986;2:261–276.Google Scholar
  21. 21.
    21. Petersen RC, Smith GE, Waring SC,. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999;56:303–308.PubMedGoogle Scholar
  22. 22.
    22. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med 2004;256:183–194.PubMedGoogle Scholar
  23. 23.
    23. Larrabee GJ, Crook TH. Estimated prevalence of age-associated memory impairment derived from standardized tests of memory function. Int Psychogeriatr 1994;6:95–104.PubMedGoogle Scholar
  24. 24.
    24. Morris JC, Price AL. Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease. J Mol Neurosci 2001;17:101–118.PubMedGoogle Scholar
  25. 25.
    25. Guillozet AL, Weintraub S, Mash DC,. Neurofibrillary tangles, amyloid, and memory in aging and mild cognitive impairment. Arch Neurol 2003;60:729–736.PubMedGoogle Scholar
  26. 26.
    26. Larner AJ. Getting it wrong: the clinical misdiagnosis of Alzheimer's disease. Int J Clin Pract 2004;58:1092–1094.PubMedGoogle Scholar
  27. 27.
    27. Hoffman RS. Diagnostic errors in the evaluation of behavioral disorders. JAMA 1982;248:964–967.PubMedGoogle Scholar
  28. 28.
    28. Ross GW, Abbott RD, Petrovich H,. Frequency and characteristics of silent dementia among elderly Japanese-American men. The Honolulu-Asia Aging Study. JAMA 1997;277:800–805.PubMedGoogle Scholar
  29. 29.
    29. Ryan DH. Misdiagnosis in dementia: comparisons of diagnostic error rate and range of hospital investigation according to medical specialty. Int J Geriatr Psychiatr 1994;9:141–147.Google Scholar
  30. 30.
    30. Tombaugh TN, McIntyre NJ. The mini-mental state examination: a comprehensive review. J Am Geriatr Soc 1992;40:922–935.PubMedGoogle Scholar
  31. 31.
    31. Crum RM, Anthony JC, Bassett SS,. Population-based norms for the Mini-Mental State Examination by age and educational level. JAMA 1993;12:2386–2391.Google Scholar
  32. 32.
    32. Bleecker ML, Bolla-Wilson K, Kawas C,. Age-specific norms for the Mini-Mental State Exam. Neurology 1988;38:1565–1568.PubMedGoogle Scholar
  33. 33.
    33. Jonker C, Geerlings MI, Schmand B. Are memory complaints predictive for dementia? A review of clinical and population-based studies. Int J Geriatr Psychiatr 2000;15:983–991.Google Scholar
  34. 34.
    34. Jorm AF, Butterworth P, Anstey KJ,. Memory complaints in a community sample aged 60–64 years: associations with cognitive functioning, psychiatric symptoms, medical conditions, APOE genotype, hippocampus and amygdala volumes, and white-matter hyperintensities. Psychol Med 2004;34:1495–1506.PubMedGoogle Scholar
  35. 35.
    35. Cacchione PZ, Powlishta KK, Grant EA,. Accuracy of collateral source reports in very mild to mild dementia of the Alzheimer type. J Am Geriatr Soc 2003;51:819–823.PubMedGoogle Scholar
  36. 36.
    36. Mega MS, Cummings JL, Fiorello T,. The spectrum of behavioral changes in Alzheimer's disease. Neurology 1996;46:130–135.PubMedGoogle Scholar
  37. 37.
    37. Stern Y, Alpert M, Brandt J,. Utility of extrapyramidal signs and psychosis as predictors of cognitive and functional decline, nursing home admission and death in Alzheimer's disease. Prospective analysis from the Predictors Study. Neurology 1994;44:2300–2307.PubMedGoogle Scholar
  38. 38.
    38. Lerner AJ, Hedera P, Koss E,. Delirium in Alzheimer disease. Alzheim Dis Assoc Disord 1997;11:16–20.Google Scholar
  39. 39.
    39. Francis J, Kapoor WN. Prognosis after hospital discharge of older medical patients with delirium. J Am Geriatr Soc 1992;40:601–606.PubMedGoogle Scholar
  40. 40.
    40. Devanand DP, Sano M, Tang MX,. Depressed mood and the incidence of Alzheimer's disease in the elderly living in the community. Arch Gen Psychiatr 1996;53:175–182.PubMedGoogle Scholar
  41. 41.
    41. Reifler BV. Diagnosing Alzheimer's disease in the presence of mixed cognitive and affective symptoms. Int Psychogeriatr 1997;9(Suppl 1):59–64.PubMedGoogle Scholar
  42. 42.
    42. Derouesne C, Thibault S, Lagha-Pierucci S,. Decreased awareness of cognitive deficits in patients with mild dementia of the Alzheimer type. Int J Geriatr Psychiatr 1999;14:1019–1030.Google Scholar
  43. 43.
    43. desRosiers G, Hodges JR, Berrios G. The neuropsychological differentiation of patients with very mild Alzheimer's disease and/or major depression. J Am Geriatr Soc 1995;43:1256–1263.PubMedGoogle Scholar
  44. 44.
    44. Visser PJ, Verhey FR, Ponds RW,. Distinction between preclinical Alzheimer's disease and depression. J Am Geriatr Soc 2000;48:479–484.PubMedGoogle Scholar
  45. 45.
    45. Alexopoulos GS, Meyers BS, Young RC,. The course of geriatric depression with “reversible dementia”: a controlled study. Am J Psychiatr 1993;150:1693–1699.PubMedGoogle Scholar
  46. 46.
    46. Knopman DS, DeKosky ST, Cummings JL,. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56:1143–1153.PubMedGoogle Scholar
  47. 47.
    47. Gilewski MJ, Zelinski EM, Schaie KW. The Memory Functioning Questionnaire for assessment of memory complaints in adulthood and old age. Psychol Aging 1990;5:482–490.PubMedGoogle Scholar
  48. 48.
    48. Pfeffer RI, Kurosaki TT, Harrah CH Jr,. Measurement of functional activities in older adults in the community. J Gerontol 1982;37:323–329.PubMedGoogle Scholar
  49. 49.
    49. Ercoli LM, Siddarth P, Huang S-C,. Perceived loss of memory ability and cerebral metabolic decline in persons with the apolipoprotein e-4 genetic risk for Alzheimer's disease. Arch Gen Psychiatr 2006;63:442–448.PubMedGoogle Scholar
  50. 50.
    50. Schmand B, Jonker C, Hooijer C,. Subjective memory complaints may announce dementia. Neurology 1996;46:121–125.PubMedGoogle Scholar
  51. 51.
    51. Roman GC. Brain hypoperfusion: a critical factor in vascular dementia. Neurol Res 2004;26:454–458.PubMedGoogle Scholar
  52. 52.
    52. Munro CA, Saxton J, Butters MA. The neuropsychological consequences of abstinence among older alcoholics: a cross-sectional study. Alcohol Clin Exp Res 2000;24:1510–1516.PubMedGoogle Scholar
  53. 53.
    53. Delgoda R, Westlake AC. Herbal interactions involving cytochrome p450 enzymes: a mini review. Toxicol Rev 2004;23:239–249.PubMedGoogle Scholar
  54. 54.
    54. Roman GC, Tatemichi TK, Erkinjuntti T,. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993;43:250–260.PubMedGoogle Scholar
  55. 55.
    55. McKeith IG, Perry EK, Perry RH. Report of the second dementia with Lewy body international workshop: diagnosis and treatment. Consortium on Dementia with Lewy Bodies. Neurology 1999;22:902–905.Google Scholar
  56. 56.
    56. McKeith LG, Galasko D, Kosaka K,. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB international workshop. Neurology 1996;47:1113–1124.PubMedGoogle Scholar
  57. 57.
    Practice parameter for diagnosis and evaluation of dementia (summary statement). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 1994;44:2203–2206.Google Scholar
  58. 58.
    58. Folstein MF, Folstein SE, McHugh PR. “Mini-Mental State.” A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–198.PubMedGoogle Scholar
  59. 59.
    59. Brayne C, Calloway P. The association of education and socioeconomic status with the Mini Mental State Examination and the clinical diagnosis of dementia in elderly people. Age Aging 1990;19:91–96.Google Scholar
  60. 60.
    60. Bleecker ML, Bolla-Wilson K, Kawas C,. Age-specific norms for the Mini-Mental State Exam. Neurology 1988;38:1565–1568.PubMedGoogle Scholar
  61. 61.
    61. Crum RM, Anthony JC, Bassett SS,. Population-based norms for the Mini-Mental State Examination by age and educational level. JAMA 1993;269:2386–2391.PubMedGoogle Scholar
  62. 62.
    62. Galasko D, Klauber MR, Hofstetter CR,. The Mini-Mental State Examination in the early diagnosis of Alzheimer's disease. Arch Neurol 1990;47:49–52.PubMedGoogle Scholar
  63. 63.
    63. Commenges D, Gagnon M, Letenneur L,. Improving screening for dementia in the elderly using, Mini-Mental State Examination subscores, Benton's Visual Retention Test, and Isaacs' Set Test. Epidemiology 1992;3:185–188.PubMedGoogle Scholar
  64. 64.
    Strub RL, Black FW. The Mental Status Examination in Neurology, 2nd ed. Philadelphia: F. A. David, 1986.Google Scholar
  65. 65.
    65. Coffey CD, Cummings JL. The American Psychiatric Press Textbook of Geriatric Neuropsychiatry. Washington, DC: American Psychiatric Press, 2000.Google Scholar
  66. 66.
    66. Morris JC, Mohs RC, Rogers H,. Consortium to establish a registry for Alzheimer's disease (CERAD) clinical and neuropsychological assessment of Alzheimer's disease. Psychopharm Bull 1988;24:641–652.Google Scholar
  67. 67.
    67. Mant A, Eyland EA, Pond DC,. Recognition of dementia in general practice: comparison of general practitioners' opinions with assessments using the Mini-Mental State Examination and Blessed dementia rating scale. Fam Pract 1988;5:184–188.PubMedGoogle Scholar
  68. 68.
    68. McCartney JR, Palmateer LM. Assessment of cognitive deficit in geriatric patients: a study of physician behavior. J Am Geriatr Soc 1985;33:467–471.PubMedGoogle Scholar
  69. 69.
    69. Ross GW, Abbott RD, Petrovitch H,. Frequency and characteristics of silent dementia among elderly Japanese-American men: the Honolulu-Asia Aging Study. JAMA 1997;277:800–805.PubMedGoogle Scholar
  70. 70.
    70. Ryan DH. Misdiagnosis in dementia: comparisons of diagnostic error rate and range of hospital investigation according to medical specialty. Int J Geriatr Psychiatr 1994;9:141–147.Google Scholar
  71. 71.
    71. Watson LC, Lewis CL, Fillenbaum GG. Asking family about memory loss. Is it helpful? J Gen Intern Med 2005;20:28–32.PubMedGoogle Scholar
  72. 72.
    72. Chodosh J, Petitti DB, Elliott M,. Physician recognition of cognitive impairment: evaluating the need for improvement. J Am Geriatr Soc 2004;52:1051–1059.PubMedGoogle Scholar
  73. 73.
    73. Silverman DH, Small GW. Prompt identification of Alzheimer's disease with brain PET imaging of a woman with multiple previous diagnoses of other neuropsychiatric conditions. Am J Psychiatr 2002;159:1482–1488.PubMedGoogle Scholar
  74. 74.
    74. Silverman DH. Brain F-18-FDG PET in the diagnosis of neurodegenerative dementias: comparison with perfusion SPECT and with clinical evaluations lacking nuclear imaging. J Nucl Med 2004;45:594–607.PubMedGoogle Scholar
  75. 75.
    75. Chow TW. Treatment approaches to symptoms associated with frontotemporal degeneration. Curr Psychiatry Rep 2005;7:376–380.PubMedGoogle Scholar
  76. 76.
    76. Chang CY, Silverman DH. Accuracy of early diagnosis and its impact on the management and course of Alzheimer's disease. Expert Rev Mol Diagn 2004;4:63–69.PubMedGoogle Scholar
  77. 77.
    77. Reiman EM, Caselli RJ, Yun LS,. Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E [see comments]. N Engl J Med 1996;334:752–758.PubMedGoogle Scholar
  78. 78.
    78. Small GW, Mazziotta JC, Collins MT,. Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. JAMA 1995;273:942–947.PubMedGoogle Scholar
  79. 79.
    79. Small GW, Ercoli LM, Silverman DH,. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc Natl Acad Sci USA 2000;97:6037–6042.PubMedGoogle Scholar
  80. 80.
    80. de Leon MJ, Convit A, Wolf OT,. Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/poitron-emission tomography (FDG/PET). Proc Natl Acad Sci USA 2001;98:10966–10971.PubMedGoogle Scholar
  81. 81.
    81. Small GW, La Rue A, Komo S,. Predictors of cognitive change in middle-aged and older adults with memory loss. Am J Psychiatr 1995;152:1757–1764.PubMedGoogle Scholar
  82. 82.
    82. Kuhl DE, Small GW, Riege WH,. Cerebral metabolic patterns before diagnosis of probable Alzheimer's disease. J Cereb Blood Flow Metab 1987;7(Suppl 1):S406.Google Scholar
  83. 83.
    83. Chetelat G, Desgranges B, de la Sayette V,. Mild cognitive impairment: can FDG-PET predict who is to rapidly convert to Alzheimer's disease? Neurology 2003;60:1374–1377.PubMedGoogle Scholar
  84. 84.
    84. Anchisi D, Borroni B, Franceschi M,. Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease. Arch Neurol 2005;62:1728–1733.PubMedGoogle Scholar
  85. 85.
    85. Silverman DH, Gambhir SS, Huang HW,. Evaluating early dementia with and without assessment of regional cerebral metabolism by PET: a comparison of predicted costs and benefits. J Nucl Med 2002;43:253–266.PubMedGoogle Scholar
  86. 86.
    86. Moulin-Romsee G, Maes A, Silverman D,. Cost-effectiveness of F-18-fluorodeoxyglucose positron emission tomography in the assessment of early dementia from a Belgian and European perspective. Eur J Neurol 2005;12:254–263.PubMedGoogle Scholar
  87. 87.
    87. Silverman DH, Small GW, Chang CY,. Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome. JAMA 2001;286:2120–2127.PubMedGoogle Scholar
  88. 88.
    Malouf R, Birks J. Donepezil for vascular cognitive impairment. Cochrane Database Syst Rev 2004;1:CD004395.Google Scholar
  89. 89.
    89. McKeith I, Del Ser T, Spano P,. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000;356:2031–2036.PubMedGoogle Scholar
  90. 90.
    90. Roman GC, Wilkinson DG, Doody RS,. Donepezil in vascular dementia: combined analysis of two large-scale clinical trials. Dement Geriatr Cogn Disord 2005;20:338–344.PubMedGoogle Scholar
  91. 91.
    Memantine for dementia. Cochrane Database Syst Rev 2005;20:CD003154.Google Scholar
  92. 92.
    92. Sabbagh MN, Hake AM, Ahmed S,. The use of memantine in dementia with Lewy bodies. J Alzheimers Dis 2005;7:285–289.PubMedGoogle Scholar
  93. 93.
    93. Ridha BH, Josephs KA, Rossor MN. Delusions and hallucinations in dementia with Lewy bodies: worsening with memantine. Neurology 2005;65(3):481–482.PubMedGoogle Scholar
  94. 94.
    94. Chaytor N, Schmitter-Edgecombe M. The ecological validity of neuropsychological tests: a review of the literature on everyday cognitive skills. Neuropsychol Rev 2003;13:181–197.PubMedGoogle Scholar
  95. 95.
    95. Teng EL, Manly JJ. Neuropsychological testing: helpful or harmful? Alzheimer Dis Assoc Disord 2005;19:267–271.PubMedGoogle Scholar
  96. 96.
    96. Saxton J, Lopez OL, Ratcliff G,. Preclinical Alzheimer disease: neuropsychological test performance 1.5 to 8 years prior to onset. Neurology 2004;63:2341–2347.PubMedGoogle Scholar
  97. 97.
    97. Tierney MC, Yao C, Kiss A,. Neuropsychological tests accurately predict incident Alzheimer disease after 5 and 10 years. Neurology 2005;64:1853–1859.PubMedGoogle Scholar
  98. 98.
    98. Mortimer JA, Borenstein AR, Gosche KM,. Very early detection of Alzheimer neuropathology and the role of brain reserve in modifying its clinical expression. J Geriatr Psychiatry Neurol 2005;18:218–223.PubMedGoogle Scholar
  99. 99.
    99. Saunders AM, Strittmatter WJ, Schmechel D,. Association of apolipoprotein E allele E4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993;43:1467–1472.PubMedGoogle Scholar
  100. 100.
    100. Corder EH, Saunders AM, Strittmatter WJ,. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993;261:921–923.PubMedGoogle Scholar
  101. 101.
    101. Pitner JK, Bachman DL. A synopsis of the practice parameters on dementia from the American Academy of Neurology on the diagnosis of dementia. Consult Pharm 2004;19:52–63.PubMedGoogle Scholar
  102. 102.
    102. Roberts JS, Cupples LA, Relkin NR,. Genetic risk assessment for adult children of people with Alzheimer's disease: the Risk Evaluation and Education for Alzheimer's Disease (REVEAL) study. J Geriatr Psychiatry Neurol 2005;18:250–255.PubMedGoogle Scholar
  103. 103.
    103. Zick CD, Mathews CJ, Roberts JS,. Genetic testing for Alzheimer's disease and its impact on insurance purchasing behavior. Health Aff (Millwood) 2005;24:483–490.Google Scholar
  104. 104.
    Loy C, Schneider L. Galantamine for Alzheimer’s disease and mild cognitive impairment. Cochrane Database Syst Rev 2006;25:CD001747.Google Scholar
  105. 105.
    105. Petersen RC, Thomas RG, Grundman M,. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 2005;352:2379–2388.PubMedGoogle Scholar
  106. 106.
    106. Salloway S, Ferris S, Kluger A,. Donepezil 401 Study Group. Efficacy of donepezil in mild cognitive impairment: a randomized placebo-controlled trial. Neurology 2004;63(4):651–657.PubMedGoogle Scholar
  107. 107.
    107. Mielke R, Heiss WD. Positron emission tomography for diagnosis of Alzheimer's disease and vascular dementia. J Neural Transm Suppl 1998;53:237–250.PubMedGoogle Scholar
  108. 108.
    108. Alexopoulos GS. Vascular disease, depression, and dementia. J Am Geriatr Soc. 2003;51:1178–1180.PubMedGoogle Scholar
  109. 109.
    109. Camus V, Kraehenbuhl H, Preisig M,. Geriatric depression and vascular diseases: what are the links? J Affect Disord 2004;81:1–16.PubMedGoogle Scholar
  110. 110.
    110. Lobotesis K, Fenwick JD, Phipps A,. Occipital hypoperfusion on SPECT in dementia with Lewy bodies but not AD. Neurology 200113;56:643–649.Google Scholar
  111. 111.
    111. Minoshima S, Foster NL, Sima AA,. Alzheimer's disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation. Ann Neurol 2001;50:358–365.PubMedGoogle Scholar
  112. 112.
    112. Duara R, Barker W, Luis CA. Frontotemporal dementia and Alzheimer's disease: differential diagnosis. Dement Geriatr Cogn Disord 1999;10(Suppl 1):37–42.PubMedGoogle Scholar
  113. 113.
    113. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 1991;82:239–259.PubMedGoogle Scholar
  114. 114.
    114. Price JL, Morris JC. Tangles and plaques in nondemented aging and “preclinical” Alzheimer's disease. Ann Neurol 1999;45:358–368.PubMedGoogle Scholar
  115. 115.
    115. Klunk WE, Wang Y, Huang GF,. The binding of 2-(4′-ethylaminophenyl)benzothiazole to postmortem brain homogenates is dominated by the amyloid component. J Neurosci 2003;23:2086–2092.PubMedGoogle Scholar
  116. 116.
    116. Shoghi-Jadid K, Small GW, Agdeppa ED,. Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer's disease. Am J Geriatr Psychiatry 2002;10:24–35.PubMedGoogle Scholar
  117. 117.
    117. Small GW, Kepe V, Ercoli L,. Positron emission tomography scanning of cerebral amyloid and tau deposits in mild cognitive impairment. N Engl J Med 2006;355:2652–2663.PubMedGoogle Scholar
  118. 118.
    118. Kung HF, Kung MP, Zhuang ZP,. Iodinated tracers for imaging amyloid plaques in the brain. Mol Imaging Biol 2003;5:418–426.PubMedGoogle Scholar
  119. 119.
    119. Klunk WE, Engler H, Nordberg A,. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004;55:306–319.PubMedGoogle Scholar
  120. 120.
    Small GW, Kepe V, Huang S-C, et al. In vivo brain imaging of tau aggregation in frontal temporal dementia using [F-18]FDDNP positron emission tomography. 9th International Conference on Alzheimer’s Disease and Related Disorders, 2004.Google Scholar
  121. 121. P
    121. Passchier J, van Waarde A, Vaalburg W, Willemsen ATM. On the quantitation of [18F]MPPF binding to 5-HT1A receptors in the human brain. J Nucl Med 2001:42;1025–1031.Google Scholar
  122. 122.
    122. Kepe V, Barrio JR, Huang SC,. Serotonin 1A receptors in the living brain of Alzheimer's disease patients. Proc Natl Acad Sci USA 2006;103:702–707.PubMedGoogle Scholar
  123. 123.
    Potkin SG. Neuroimaging techniques and applications. American Psychiatric Association Syllabus and Scientific Proceedings 1999;28C:256.Google Scholar
  124. 124.
    124. Mega MS, Cummings JL, Masterman DM,. Cognitive and metabolic responses to metrifonate therapy in Alzheimer's disease. Neuropsychiatr Neuropsychol Behav Neurol 2001;14:63–68.Google Scholar
  125. 125.
    125. Fox NC, Black RS, Gilman S,. Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology 2005;64:1563–1572.PubMedGoogle Scholar
  126. 126.
    126. Jack CR Jr, Dickson DW, Parisi JE. Antemortem MRI findings correlate with hippocampal neuropathology in normal aging and dementia. Neurology 2002;58:750–757.PubMedGoogle Scholar
  127. 127.
    127. Silbert LC, Quinn JF, Moore MM,. Changes in premorbid brain volume predict Alzheimer's disease pathology. Neurology 2003;61: 487–492.Google Scholar
  128. 128.
    128. Agdeppa ED, Kepe V, Petric A,. In vitro detection of (S)-naproxen and ibuprofen binding to plaques in the Alzheimer's brain using the positron emission tomography molecular imaging probe 2-(1-{6-[(2-[18F]fluoroethyl)(methyl)amino]-2-aphthyl}ethylidene)malononitrile. Neuroscience 2003;117:723–730.PubMedGoogle Scholar
  129. 129.
    129. Small GW, Silverman DHS, Siddarth P, Ercoli LM, Miller KJ, Wright BC, Bookheimer SY, Barrio JR, Phelps ME. Effects of a 14-day healthy aging lifestyle program on cognition and brain function. Am J Geriatr Psychiatr 2006;14:538–545.Google Scholar

Copyright information

© Springer Science + Business Media, LLC 2009

Authors and Affiliations

  • Linda M. Ercoli
    • 1
  • Gary W. Small
    • 2
  1. 1.Department of Psychiatry and Biobehavioral Sciencesthe Semel Institute for Neuroscience and Human Behavior and the Resnick Neuropsychiatric Hospital at the University of CaliforniaCA
  2. 2.Parlow-Solomon Professor on Aging, Department of PsychiatryDavid Geffen School of Medicine at University of California Los AngelesCA

Personalised recommendations